TrioBiotics Pharma AG
Triton Biopharma AG: Michael Jarmolowich appointed as Board Member
Triton Biopharma AG / Change of Personnel Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- ZUG, Switzerland - February 19, 2009 - TRITON BIOPHARMA AG (Frankfurt: 4ON) today announced the appointment of Mr. Michael Jarmolowich to the Board of Directors for Triton BioPharma AG. Mr. Jarmolowich is also presently a Director for Deutsche Bank Securities in New York and was the former Vice President of Credit Suisse Private Bank in New York. He began his career in investment banking and finance with Lehman Brothers Private Bank upon completion of the MBA Associate program at Lehman Brothers New York in 1999. He has established an impressive portfolio of business in the area of private equity finance, holding key positions with leading investment institutions. For the last 9 years, Mr. Jarmolowich has focused primarily on advising private companies about the capital markets and creating liquidity for founding members. Prior to his introduction to the world of finance, Mr. Jarmolowich was a professional football player in the National Football League (NFL), and previously worked as a Sales Executive for Automatic Data Processing New York. He received an MBA from Farleigh Dickinson University in 2000, and a Bachelor of Arts in Speech Communications of the University of Maryland in 1992. 'One of our main objectives in establishing a successful corporate structure was to form a highly effective Board of Directors, representing a balanced profile of members with business experience and leading scientists with proven research and industry expertise', said Angelo Boujos, Chairman of the Board of Triton BioPharma AG. Mr. Boujos continued, 'Mr. Jarmolowich will be a valuable member of our Board in setting corporate directives, and understanding how decisions regarding our growth and development will benefit shareholder interests.' About Triton BioPharma AG Triton BioPharma AG is a holding company and is only active through its wholly-owned subsidiaries, Triton BioPharma SARL and Triton BioPharma LLC. These subsidiary companies are responsible for all of Triton's biotechnology operations and R&D activities in the discovery, development, and commercialization of novel drug leads from marine sources for the global market. Triton's current pipeline includes advanced preclinical candidates in the treatment of neuropsychiatric disorders, including depression and anxiety, inflammation, infectious diseases and cancer. The company was founded in 2008 and has its corporate office in Toronto, Canada. Contact: Investor Relations Europe: Milestone Media AG, Zug (Switzerland) Phone: +41 (0)41 5000 769 Fax: +41 (0)41 5000 728 E-mail: info@milestonemedia.ch For more information, visit www.tritonbiopharma.com 19.02.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden